期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性白血病多药耐药机制的研究进展 被引量：1

Progress of Multidrug Resistance Mechanisms in Acute Leukemia
下载PDF
导出
摘要 迄今为止,化学药物治疗（化疗）仍是急性白血病（acute leukemia,AL）治疗的主要方法,AL细胞对抗癌药物的耐药是AL化疗失败、疾病复发的一个主要根源.AL细胞耐药分为原药耐药（primary drug resistance,PDR）和多药耐药（multidrug resistance,MDR）,其中白血病细胞对许多结构和功能都完全不同的药物的交叉耐药性（MDR）是AL的一种主要的耐药形式.由于AL患者的个体差异及白血病细胞的异质性,现在认为MDR的产生是多因素、多机制综合作用的结果.
作者 高风英 于民海
机构地区 潍坊医学院血液学教研室 潍坊医学院附属人民医院血液科
出处 《中国临床医学》 北大核心 2007年第3期445-447,共3页 Chinese Journal of Clinical Medicine
关键词 多药耐药机制 急性白血病 化学药物治疗 白血病细胞 AL细胞 化疗失败 交叉耐药性 抗癌药物
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Chauncey TR.Drug resistance mechanisms in acute leukemia[J].Curr Opin Oncol,2001,13(1):21-26.
  • 2Yu LJ,Matias J,Seudiero DA,et al.P450 enzyme expression Patterns in the NCI human tumor cell line panel[J].Drug Metab Dispos,2001,29:304-312.
  • 3Arceci RJ.Can multidrug resistance mechanisms be modified?[J]Br J Haematol,2000,110:285-291.
  • 4Leith CP,Kopecky KJ,Chen IM,et al.Freguency and clinical significance of the expression of the multidrug resistance protein MDR1/P-glycoprotein,MRP1,and LRP in acute myeloid leukemia[J].Blood,1999,94:1086-1099.
  • 5Kudoh K,Ramanna M,Ravatn R,et al.Monitoring the expression Profiles of doxorubicin-induced and doxorubicin-resistant cancer by cDNA microarray[J].Cancer Res,2000,60:4161-4166.
  • 6Legrand O,Simonin G,Zittoun R,et al.Lung resistance Protein (LRP)gene expression in adult acute myeloid leukemia:a critical evaluation by three techniques.Leukemia[J],1998,12:1367-1374.
  • 7del Poeta G,Stasi P,Venditti A,et al.Prognostic value of cell maker analysis in de novo acute myeloid leukemia[J].Leukemia,1994,8(3):388.
  • 8Senent L,Jarque L,Martin C,et al.P-glycoprotein expression and prognostic value in acute myeloid leukemia.Haematologica[J].1998,83:783-787.
  • 9Filipits M,stranzl T,Pohl G,et al.Drug resistance factors in acute myeloid leukemia:a comparative analysis[J].leukemia,2000,14:68-76.
  • 10Lepelley P,Poulain S,Grardel N,et al.Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes[J].Leukemia Lymphoma,1998,29:547-551.

二级参考文献24

  • 1Steinherz LJ,Steinherz PG,Tan CT, et al. Cardiac toxicity 4 to 20years after completing anthracycline therapy[J]. JAMA, 1991,266(12): 1672 - 1677.
  • 2Shan KA, Lincoff M, Young JB. Anthracycline - induced cardiocytoxicity[J]. Annals of Internal Medicin, 1996,125 (1): 47 - 58.
  • 3Kremer LCM, Vander Pal HJH, Offringa M, et al. Frequency and risk factors of subcliical cardiotoxicity after anthracycline therapy in children: A systematic review[J]. Annals Oncol, 2002, 13:819 -829.
  • 4Bu'Lock FA, Martin RP, Mott MG. Increased risk of cardiac dysfunction after anthracyclines in girls[J]. Med Pediatr Oncol, 1995,24(2): 143 - 144.
  • 5Horenstein MS, Vander Heide RS, L'ecuyer TJ. Molecular basis of anthracycline- induced cardiotoxicity and its prevention [J]. Mol Genet Metab, 2000,71 ( 1 - 2): 436 - 444.
  • 6Giorgio M, Gaetano C, Elena M. Role of iron in anthracycline cardiotoxicity: new tunes for an old song[J]? FASEB J, 1999, 13(2): 199 - 212.
  • 7Swift L, McHowat J, Sarvazyan N. Inhibition of membrane - associated calcium - independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity[J]. Cancer Res, 2003,63(18) :5992- 5998.
  • 8Zhu WD, Zou YZ, Aikawa R, et al. MAPK superfamily plays an important role in daunomycin - induced apoptosis of cardiac myocytes[J]. Circulation,1999,100(20):2100-2107.
  • 9Kim Y, Ma AG, Kitta K, et al. Anthracycline- induced suppression of GATA- 4 transcription factor: implication in the regulation of cardiac myocyte apoptosis[J]. Mol Pharmacol, 2003,63 (2): 368 -377.
  • 10Safra T. Cardiac safety of liposomal anthracyclines[J]. Oncologist,2003,8 (suppl 2): S17 - S24.

共引文献17

同被引文献5

引证文献1

二级引证文献1

中国临床医学
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部